AspenBio Pharma Inc. (APPY, Financial) filed Quarterly Report for the period ended 2010-09-30.
Aspenbio Pharma Inc. has a market cap of $12.4 million; its shares were traded at around $0.49 with and P/S ratio of 42.8.
Research and development expenses in the 2010 period totaled $4,399,000, which is a $1,535,000 or 26% decrease as compared to the 2009 period. Development efforts and advances on the appendicitis test, including product development advances, clinical trial and regulatory related activities comprised the primary expenses. Clinical trial and regulatory related expenses were approximately $74,000 lower in the nine months ended September 30, 2010 primarily due to the AppyScore clinical trial that commenced in the second half of 2009 and was completed earlier in 2010. Development expenses incurred for advances on the cassette and reader program were approximately $1,104,000 lower in 2010 as compared to 2009, primarily due to substantial completion of development activities by the product development firms. Expenses incurred in connection with product and market related studies were approximately $297,000 lower in 2010 as compared to 2009. Hiring of additional scientific personnel for product development resulted in approximately $137,000 of additional expenses in the 2010 period. Direct development expenses on the single-chain animal health products decreased by approximately $200,000 in the 2010 period.
Research and development expenses in the 2010 period totaled $1,043,000, which is a $1,232,000 or 54% decrease as compared to the 2009 period. Development efforts and advances on the appendicitis test, including product development advances, clinical trial and regulatory related activities comprised the primary expenses. Development expenses incurred for advances on the cassette and reader program were approximately $643,000 lower in 2010 as compared to 2009, primarily due to substantial completion of development activities by the product development firms. Clinical trial and regulatory related expenses were approximately $661,000 lower in the three months ended September 30, 2010 primarily due to the AppyScore clinical trial that commenced in the second half of 2009 and was completed earlier in 2010. Expenses incurred in connection with product and market related studies were approximately $47,000 lower in 2010 as compared to 2009. Hiring of additional scientific personnel for product development resulted in approximately $7,000 of additional expenses in the 2010 period. Direct development expenses on the single-chain animal health products increased by approximately $52,000 in the 2010 period. Research and development costs also increased $57,000 resulting from patent impairment costs related to not pursuing specific patents that were deemed to be not economically beneficial.
For financial reporting purposes, the up-front license fees received from the Novartis License Agreement, net of the amounts due to WU, have been recorded as deferred revenue and are amortized over the term of the Novartis License Agreement. Milestone revenue is or will be recognized into income commencing with the date such milestones are achieved. During the nine months ended September 30, 2010, milestones totaling $100,000 were achieved, triggering the commencement of amortization of $100,000 of deferred revenue. As of September 30, 2010, deferred revenue of $746,062 has been classified as a current liability and $651,401 has been classified as a long-term liability. The current liability includes the remaining milestone revenue that is subject to achievement conditions and also includes the next twelve months portion of the amortizable milestone revenue. During each of the nine month periods ended September 30, 2010 and 2009, $50,629 and $47,960, respectively, was recorded as the amortized license fee revenue arising from the Novartis License Agreement.
Net cash consumed by operating activities was $8,572,000 during the nine months ended September 30, 2010. Cash was consumed by the loss of $10,346,000, less non-cash expenses relating to stock-based compensation totaling $1,847,000 and depreciation, amortization and other totaling $502,000, net of amortized license fee revenues of $51,000. Included in the 2010 write down of assets is $95,000 in patent impairment costs related to specific patents that we are no longer pursuing and a $103,000 non-cash charge incurred to write down antigen raw material inventory. A decrease in accounts receivable of $9,000 resulting from lower base antigen sales levels provided cash. Inventory levels decreased by $96,000, from net sales activities associated with management s decision late in 2009 to substantially suspend the production of antigen products as a result of its strategic decision to focus available scientific resources on appendicitis and single-chain animal product development. A decrease in prepaid and other current assets of $35,000 provided cash. Cash consumed in operations included a decrease of $716,000 in accounts payable and accrued expenses, primarily due to the decrease in expenses related to the recent completion of the Company s AppyScore clinical trial.
Net cash consumed by operating activities was $7,774,000 during the nine months ended September 30, 2009. Cash was consumed by the loss of $10,331,000, less non-cash expenses of $1,215,000 for stock-based compensation and $261,000 for depreciation and amortization and other non-cash items. Our base antigen business is generally not significant to our operations and therefore does not generally significantly impact operating cash flows. As of September 30, 2009 inventories had increased by $124,000 due to receipt of a recent raw material supply order and prepaid expenses and other current assets generated cash of $676,000 primarily related to collection of shared costs incurred under the Novartis agreement, payable by Novartis, in the amount of $425,000.
Read the The complete Report
Aspenbio Pharma Inc. has a market cap of $12.4 million; its shares were traded at around $0.49 with and P/S ratio of 42.8.
Highlight of Business Operations:
Selling, general and administrative expenses in the nine months ended September 30, 2010, totaled $5,934,000, which is a $1,506,000 or 34% increase as compared to the 2009 period. Hiring of additional management personnel to advance the AppyScoreâ„¢ product resulted in approximately $441,000 of additional expenses in the 2010 period. Approximately $720,000 in additional stock based compensation expense was recorded in 2010 over 2009 amounts. Included in the stock based compensation increase is $154,000 related to options granted to animal health advisors. Selling, general and administrative expenses also increased by $191,000 in insurance related costs primarily due to increased medical benefits costs and increases in the Company s insurance limits. A $157,000 increase in legal fees was incurred during the 2010 period directly related primarily to pending litigations matters.Research and development expenses in the 2010 period totaled $4,399,000, which is a $1,535,000 or 26% decrease as compared to the 2009 period. Development efforts and advances on the appendicitis test, including product development advances, clinical trial and regulatory related activities comprised the primary expenses. Clinical trial and regulatory related expenses were approximately $74,000 lower in the nine months ended September 30, 2010 primarily due to the AppyScore clinical trial that commenced in the second half of 2009 and was completed earlier in 2010. Development expenses incurred for advances on the cassette and reader program were approximately $1,104,000 lower in 2010 as compared to 2009, primarily due to substantial completion of development activities by the product development firms. Expenses incurred in connection with product and market related studies were approximately $297,000 lower in 2010 as compared to 2009. Hiring of additional scientific personnel for product development resulted in approximately $137,000 of additional expenses in the 2010 period. Direct development expenses on the single-chain animal health products decreased by approximately $200,000 in the 2010 period.
Research and development expenses in the 2010 period totaled $1,043,000, which is a $1,232,000 or 54% decrease as compared to the 2009 period. Development efforts and advances on the appendicitis test, including product development advances, clinical trial and regulatory related activities comprised the primary expenses. Development expenses incurred for advances on the cassette and reader program were approximately $643,000 lower in 2010 as compared to 2009, primarily due to substantial completion of development activities by the product development firms. Clinical trial and regulatory related expenses were approximately $661,000 lower in the three months ended September 30, 2010 primarily due to the AppyScore clinical trial that commenced in the second half of 2009 and was completed earlier in 2010. Expenses incurred in connection with product and market related studies were approximately $47,000 lower in 2010 as compared to 2009. Hiring of additional scientific personnel for product development resulted in approximately $7,000 of additional expenses in the 2010 period. Direct development expenses on the single-chain animal health products increased by approximately $52,000 in the 2010 period. Research and development costs also increased $57,000 resulting from patent impairment costs related to not pursuing specific patents that were deemed to be not economically beneficial.
For financial reporting purposes, the up-front license fees received from the Novartis License Agreement, net of the amounts due to WU, have been recorded as deferred revenue and are amortized over the term of the Novartis License Agreement. Milestone revenue is or will be recognized into income commencing with the date such milestones are achieved. During the nine months ended September 30, 2010, milestones totaling $100,000 were achieved, triggering the commencement of amortization of $100,000 of deferred revenue. As of September 30, 2010, deferred revenue of $746,062 has been classified as a current liability and $651,401 has been classified as a long-term liability. The current liability includes the remaining milestone revenue that is subject to achievement conditions and also includes the next twelve months portion of the amortizable milestone revenue. During each of the nine month periods ended September 30, 2010 and 2009, $50,629 and $47,960, respectively, was recorded as the amortized license fee revenue arising from the Novartis License Agreement.
Net cash consumed by operating activities was $8,572,000 during the nine months ended September 30, 2010. Cash was consumed by the loss of $10,346,000, less non-cash expenses relating to stock-based compensation totaling $1,847,000 and depreciation, amortization and other totaling $502,000, net of amortized license fee revenues of $51,000. Included in the 2010 write down of assets is $95,000 in patent impairment costs related to specific patents that we are no longer pursuing and a $103,000 non-cash charge incurred to write down antigen raw material inventory. A decrease in accounts receivable of $9,000 resulting from lower base antigen sales levels provided cash. Inventory levels decreased by $96,000, from net sales activities associated with management s decision late in 2009 to substantially suspend the production of antigen products as a result of its strategic decision to focus available scientific resources on appendicitis and single-chain animal product development. A decrease in prepaid and other current assets of $35,000 provided cash. Cash consumed in operations included a decrease of $716,000 in accounts payable and accrued expenses, primarily due to the decrease in expenses related to the recent completion of the Company s AppyScore clinical trial.
Net cash consumed by operating activities was $7,774,000 during the nine months ended September 30, 2009. Cash was consumed by the loss of $10,331,000, less non-cash expenses of $1,215,000 for stock-based compensation and $261,000 for depreciation and amortization and other non-cash items. Our base antigen business is generally not significant to our operations and therefore does not generally significantly impact operating cash flows. As of September 30, 2009 inventories had increased by $124,000 due to receipt of a recent raw material supply order and prepaid expenses and other current assets generated cash of $676,000 primarily related to collection of shared costs incurred under the Novartis agreement, payable by Novartis, in the amount of $425,000.
Read the The complete Report
